Solara Active Pharma Sciences Limited — Others, 15-05-2025: Retirement

Solara Active Pharma Sciences Limited has announced a board meeting on the approval of the financial results for the quarter and year ended March 31, 2025. The company allotted 1 lakh shares under its ESOP and appointed Ms. Pooja Jaya Kumar as Company Secretary & Compliance Officer. It revised insider trading and related party transaction policies, appointed a new secretarial auditor for five years, reappointed its cost auditor, and named Grant Thornton Bharat LLP as internal auditors for FY26. Consolidated revenues for FY25 stood at ₹1,292 Cr, flat year-on-year, while gross margin rose sharply to 51.5%, and EBITDA turned positive at ₹214 Cr versus a loss last year. Despite intense competition in Ibuprofen, focus on margins and cost control led to debt reduction by ₹223 Cr to ₹776 Cr. The company received key regulatory certifications including USFDA zero-observation approval. A rights issue raised ₹157 Cr, partly used for debt repayment. Solara is pursuing a demerger of its CRAMS and Polymers business into Synthix Global Pharma Solutions Limited to strengthen the balance sheet and returns. FY26 outlook projects ~10% revenue growth, 15-20% EBITDA rise, strong margin expansion, working capital efficiency, and net debt to EBITDA below 1x after demerger.